Seven drugs are set to enter the market in 2019 and achieve blockbuster status by 2023.
Therapies targeting diseases characterized by genetic disorder and/or excessive immune response (including autoimmunity) dominate the list, with six agents out of the seven, and a strong showing by orphan drugs and breakthrough treatments, as well.